Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Read more about Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Read more about Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Read more about Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Read more about Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
FDA Issues Nyxoah an Approvable Letter for its Genio® System Read more about FDA Issues Nyxoah an Approvable Letter for its Genio® System
Nyxoah Raises $27 Million through its At-the-Market Offering Read more about Nyxoah Raises $27 Million through its At-the-Market Offering
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Read more about Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Read more about Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares